Terns Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amy L. Burroughs
- Full Time Employees
- 59
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1065 East Hillsdale Boulevard Foster City CA United States of America 94404
- IPO Date
- Feb 5, 2021
- CIK
- 0001831363
- Website
- ternspharma.com
- Similar Companies
- Business
- Terns Pharmaceuticals, Inc. (TERN) is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapeutics for the treatment of oncology and metabolic diseases. The company offers a pipeline of product candidates including TERN-701, a highly selective, oral BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia; TERN-601, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer; TERN-601 for breast cancer; TERN-11, an oral alpha-1,3-galactosyltransferase inhibitor for metabolic dysfunction-associated steatohepatitis; and other early-stage programs targeting oncology and rare diseases, such as TERN-811 and TERN-031 for solid tumors. These therapies aim to address unmet needs in patients with difficult-to-treat cancers and liver diseases through differentiated mechanisms of action, including allosteric inhibition and PROTACs. Terns Pharmaceuticals operates primarily in the United States and China, with headquarters in Foster City, California, and was founded in 2019. In recent developments, the company expanded its pipeline through strategic collaborations, including a 2024 licensing agreement with Sinovant Biosciences for TERN-701 rights in Asia; reported positive interim data from the Phase 1 trial of TERN-701 in 2025, advancing toward registration; initiated dosing in the Phase 1 trial for TERN-601 in mid-2025; and secured $172 million in a Series E financing round in late 2024 to support late-stage development and manufacturing. Additionally, Terns strengthened its leadership team with key hires in regulatory affairs and formed alliances for combination therapies in oncology. The company targets global markets with a focus on North America, Europe, and Asia-Pacific, serving patients through partnerships with academic institutions and contract research organizations.
Tern shares surge as it ups stakes in AI health services company Talking Medicines
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
Why Terns Pharmaceuticals Stock Rocked the Market in March
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Shareholder Alert: Ademi LLP investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Capricorn Fund Managers Ltd Takes $6.12 Million Position in Terns Pharmaceuticals, Inc. $TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Arista Networks, Block, Colgate-Palmolive, Digital Realty, Emerson Electric, MiniMed, Shake Shack, and More
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
E. Ohman J or Asset Management AB Sells 81,208 Shares of Terns Pharmaceuticals, Inc. $TERN
Terns Pharmaceuticals (NASDAQ:TERN) Sets New 12-Month High – Here’s Why